1. Home
  2. RZLT vs SGHT Comparison

RZLT vs SGHT Comparison

Compare RZLT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RZLT
  • SGHT
  • Stock Information
  • Founded
  • RZLT 2010
  • SGHT 2011
  • Country
  • RZLT United States
  • SGHT United States
  • Employees
  • RZLT N/A
  • SGHT N/A
  • Industry
  • RZLT Biotechnology: Pharmaceutical Preparations
  • SGHT Medical Specialities
  • Sector
  • RZLT Health Care
  • SGHT Health Care
  • Exchange
  • RZLT Nasdaq
  • SGHT Nasdaq
  • Market Cap
  • RZLT 819.3M
  • SGHT 193.2M
  • IPO Year
  • RZLT N/A
  • SGHT 2021
  • Fundamental
  • Price
  • RZLT $8.89
  • SGHT $4.98
  • Analyst Decision
  • RZLT Strong Buy
  • SGHT Buy
  • Analyst Count
  • RZLT 7
  • SGHT 8
  • Target Price
  • RZLT $14.86
  • SGHT $4.50
  • AVG Volume (30 Days)
  • RZLT 1.4M
  • SGHT 209.9K
  • Earning Date
  • RZLT 11-07-2025
  • SGHT 11-06-2025
  • Dividend Yield
  • RZLT N/A
  • SGHT N/A
  • EPS Growth
  • RZLT N/A
  • SGHT N/A
  • EPS
  • RZLT N/A
  • SGHT N/A
  • Revenue
  • RZLT N/A
  • SGHT $76,303,000.00
  • Revenue This Year
  • RZLT N/A
  • SGHT N/A
  • Revenue Next Year
  • RZLT N/A
  • SGHT $12.04
  • P/E Ratio
  • RZLT N/A
  • SGHT N/A
  • Revenue Growth
  • RZLT N/A
  • SGHT N/A
  • 52 Week Low
  • RZLT $2.22
  • SGHT $2.03
  • 52 Week High
  • RZLT $10.04
  • SGHT $5.32
  • Technical
  • Relative Strength Index (RSI)
  • RZLT 49.10
  • SGHT 65.67
  • Support Level
  • RZLT $9.00
  • SGHT $4.92
  • Resistance Level
  • RZLT $10.03
  • SGHT $5.16
  • Average True Range (ATR)
  • RZLT 0.54
  • SGHT 0.34
  • MACD
  • RZLT -0.06
  • SGHT 0.03
  • Stochastic Oscillator
  • RZLT 25.04
  • SGHT 82.60

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: